- recruitingPHASE2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
This study is looking at a new medicine called obinutuzumab for teenagers and children aged 5 to 17 with a kidney condition called lupus nephritis. We want to see if it's safe, how well it works, and how the body uses it.
United States · Brazil · Canada - active not recruitingPHASE1
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
This study is looking into a new medicine called felzartamab for people with lupus nephritis (LN), a kidney problem caused by lupus. Researchers want to see if it's safe and how it works to help reduce kidney damage, alongside usual treatments.
United States · Argentina · Australia - active not recruitingPHASE2
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
This study is testing a new cell therapy called CC-97540 for people with lupus and lupus kidney disease. It aims to see if it's safe and effective when other treatments haven't worked well enough.
United States · Argentina · Austria - active not recruitingPHASE1, PHASE2
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
This study is testing a new treatment called YTB323 for severe lupus that hasn't responded to other medicines. Researchers want to see if it's safe, how well it works, and how it affects the body's cells in people aged 18-65.
Australia · France · Germany - recruitingPHASE1
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
This study is testing a new medicine called FT819 for serious autoimmune diseases like lupus and vasculitis. It's looking at how safe it is and how well it works to reduce disease activity, especially in those who haven't responded to other treatments.
United States · France · Sweden - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)
This study is testing a new cell therapy called KYV-101 for people with a serious kidney condition called lupus nephritis. Researchers want to see if this treatment is safe and if it helps improve the condition. It's an early-stage study, meaning it's one of the first times this therapy is being given to people.
Germany - recruitingPHASE2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
This study is testing a new cell therapy called rapcabtagene autoleucel for severe lupus (SLE) or lupus affecting the kidneys (lupus nephritis). It aims to see how well it works and if it's safe for people whose current treatments aren't effective.
United States · Australia · Austria - active not recruitingPHASE3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
This study is testing a new medicine, ianalumab, for adults with active lupus nephritis. It compares ianalumab given every 4 or 12 weeks to a dummy medicine, alongside standard treatments, to see if it's safe and effective.
United States · Argentina · Brazil - recruitingPHASE2
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
This study looks at a new treatment called obe-cel for severe lupus affecting the kidneys (lupus nephritis). It's for people aged 12-65 whose current treatments haven't worked. The aim is to see if obe-cel can make their kidney lupus go into remission.
United States · Brazil · Greece - recruitingPHASE2
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
This study is looking at a new medicine called iptacopan for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see how well it works and if it's safe when added to standard treatments.
United States · Argentina · Brazil - active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
This study is looking at a new medicine called obinutuzumab for people with a serious kidney problem called lupus nephritis. Researchers want to see if it's safe and helps better than a dummy medicine when added to usual treatments, like steroids.
United States · Argentina · Brazil